Study wrapper · #111
GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.
Editor's note
This is a systematic review with meta-analytic components spanning seven pivotal RCTs and six meta-analyses, roughly 901 participants aged 6 to under 18, so among the study types here it sits near the top of the evidence hierarchy for pediatric GLP-1 use. The finding is clear and consistent: semaglutide 2.4 mg weekly produced the largest BMI reduction in adolescents with obesity, with liraglutide next; in youth-onset type 2 diabetes, liraglutide and dulaglutide improved HbA1c versus placebo. Gastrointestinal events (nausea, vomiting) were the most frequent, generally transient and dose-dependent, and no significant effect on linear growth or puberty was reported. The important caveat is duration and scope: the authors themselves flag that longer-term cardiovascular, bone-health, and growth outcomes remain unstudied, and 901 pooled participants is modest for a pediatric safety question. Weight this as reasonably strong short-term evidence in adolescents, with the long-term safety picture explicitly unresolved.
Plain-language abstract
This is a review that systematically gathered and combined results from the best available studies, seven randomized trials and six earlier reviews, covering about 901 children and teens aged 6 to under 18 with obesity or type 2 diabetes. The goal was to see how well GLP-1 medications work and how safe they are in young people. For weight, semaglutide at 2.4 mg per week produced the largest BMI reduction in adolescents, followed by liraglutide, which also helped in younger children. For youth-onset type 2 diabetes, liraglutide and dulaglutide lowered long-term blood sugar (HbA1c) compared with placebo. The medications also improved insulin resistance and modestly lowered triglycerides, with little change in LDL cholesterol. The most common side effects were nausea and vomiting, which were usually temporary and related to dose. Importantly, no significant effects on height growth or puberty were reported in these studies. The authors caution that longer studies are still needed to understand effects on the heart, bones, and growth over time.